Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers

Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers Publisher

Zandi M¹ ; Shafaati M² ; Shenagari M³ ; Naziri H³

Show Affiliations

1. Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
2. Department of Microbiology, Faculty Science, Jahrom Branch, Islamic Azad University, Jahrom, Iran
3. Department of Microbiology, Faculty of Medicine, Guilan University of Medical Sciences, Rasht, Iran

Source: Heliyon Published:2023

Abstract

Macrophages are essential mediators of innate immunity. Non-self-cells resist phagocytosis through the expression of the checkpoint molecule CD47. CD47, as the integrin-associated protein, is overexpressed on tumor and SARS-CoV-2-infected cells as a potential surface biomarker for immune surveillance evasion. CD47-signal-regulating protein alpha (SIRPα) interaction is a promising innate immunotarget. Previous findings based on monoclonal antibodies (mAbs) or fusion proteins that block CD47 or SIRPα have been developed in cancer research. While CD47 efficacy in infectious diseases, especially severe COVID-19 studies, is lacking, focus on macrophage-mediated immunotherapy that increases “eat me” signals in combination therapy with mAbs is optimistic. This integrin-related protein can be as a potential target to therapy for COVID-19. Here, we concentrate on the role of the CD47 signaling pathway as a novel therapeutic strategy for COVID-19-associated cancer treatment. © 2023 The Author(s)

2. Don't Eat Me/Eat Me Signals As a Novel Strategy in Cancer Immunotherapy, Heliyon (2023)

3. Dual Blockage of Both Pd-L1 and Cd47 Enhances the Therapeutic Effect of Oxaliplatin and Folfox in Ct-26 Mice Tumor Model, Scientific Reports (2023)

4. The Complex Role of Macrophages in Pancreatic Cancer Tumor Microenvironment: A Review on Cancer Progression and Potential Therapeutic Targets, Discover Oncology (2024)

5. Covid-19-Induced Autoimmune Thyroiditis: Exploring Molecular Mechanisms, Journal of Medical Virology (2023)

6. A Meta-Analysis for Prevalence of Lung Cancer Patients With Sars-Cov-2 Infection During the Covid-19 Pandemic, Eurasian Journal of Medicine and Oncology (2022)

7. 3D Bioprinting Technology to Mimic the Tumor Microenvironment: Tumor-On-A-Chip Concept, Materials Today Advances (2021)

Experts (# of related papers)

View all Related Experts

Seyed Hamidollah Ghaffari (1)

Shahab Rafieian (1)

Style	Citing Format
MLA	Zandi M, et al.. "Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers." Heliyon, vol. 9, no. 7, 2023, pp. -.
APA	Zandi M, Shafaati M, Shenagari M, Naziri H (2023). Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers. Heliyon, 9(7), -.
Chicago	Zandi M, Shafaati M, Shenagari M, Naziri H. "Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers." Heliyon 9, no. 7 (2023): -.
Harvard	Zandi M et al. (2023) 'Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers', Heliyon, 9(7), pp. -.
Vancouver	Zandi M, Shafaati M, Shenagari M, Naziri H. Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers. Heliyon. 2023;9(7):-.
BibTex	@article{ author = {Zandi M and Shafaati M and Shenagari M and Naziri H}, title = {Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers}, journal = {Heliyon}, volume = {9}, number = {7}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Zandi M AU - Shafaati M AU - Shenagari M AU - Naziri H TI - Targeting Cd47 As a Therapeutic Strategy: A Common Bridge in the Therapy of Covid-19-Related Cancers JO - Heliyon VL - 9 IS - 7 SP - EP - PY - 2023 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract